摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,4-dihydro-2,6-dimethyl-3-oxo-2H-thieno[2,3-e]-1,2-thiazine-4-carboxanilide 1,1-dioxide | 869733-54-0

中文名称
——
中文别名
——
英文名称
3,4-dihydro-2,6-dimethyl-3-oxo-2H-thieno[2,3-e]-1,2-thiazine-4-carboxanilide 1,1-dioxide
英文别名
2,6-dimethyl-1,1,3-trioxo-N-phenyl-4H-thieno[2,3-e]thiazine-4-carboxamide
3,4-dihydro-2,6-dimethyl-3-oxo-2H-thieno[2,3-e]-1,2-thiazine-4-carboxanilide 1,1-dioxide化学式
CAS
869733-54-0
化学式
C15H14N2O4S2
mdl
——
分子量
350.419
InChiKey
FIQPJGYYGZDREB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    23
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    120
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    异氰酸苯酯 在 sodium hydride 、 盐酸 作用下, 以 四氢呋喃 为溶剂, 以69%的产率得到3,4-dihydro-2,6-dimethyl-3-oxo-2H-thieno[2,3-e]-1,2-thiazine-4-carboxanilide 1,1-dioxide
    参考文献:
    名称:
    [EN] TREATMENT OF DISEASES ASSOCIATED WITH ALTERED LEVEL OF AMYLOID BETA PEPTIDES
    [FR] PROCEDE POUR TRAITER DES MALADIES ET DES ETATS ASSOCIES A UN NIVEAU MODIFIE DE PEPTIDES BETA AMYLOIDES ET NOUVEAUX COMPOSES D'ENOLCARBOXAMIDE
    摘要:
    公开号:
    WO2005110422A3
点击查看最新优质反应信息

文献信息

  • Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds
    申请人:Bornemann Klaus
    公开号:US20050277635A1
    公开(公告)日:2005-12-15
    A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid β peptides (Aβ) and/or with a changed ratio of levels of Aβ isoforms and/or with the formation of plaques containing amyloid β peptide (Aβ) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R 2 , R 3 , R 5 , R 6 , L1 and i are defined as in claim 1.
    一种治疗或预防与哺乳动物中淀粉样β肽(Aβ)异构体水平增加、Aβ异构体水平比例改变和/或含有Aβ肽的斑块形成有关的疾病或病症的方法,包括向该哺乳动物投与公式Ia、Ib中选定的化合物的治疗有效量,其中V、W、Y、R2、R3、R5、R6、L1和i的定义如权利要求1所述。
  • Method of Treating Diseases and Conditions Associated with an Altered Level of Amyloid Beta Peptides and New Enolcarboxamide Compounds
    申请人:BORNEMANN Klaus
    公开号:US20090099159A1
    公开(公告)日:2009-04-16
    A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid β peptides (Aβ) and/or with a changed ratio of levels of Aβ isoforms and/or with the formation of plaques containing amyloid β peptide (Aβ) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R 2 , R 3 , R 5 , R 6 , L 1 and i are defined as in claim 1.
    一种治疗或预防与哺乳动物中淀粉样β肽(Aβ)的同工异构体水平增加和/或Aβ同工异构体水平比例改变和/或含有Aβ同工异构体的斑块形成相关的疾病或病症的方法,包括向该哺乳动物施用从Ia、Ib公式中选择的化合物的治疗有效量,其中V、W、Y、R2、R3、R5、R6、L1和i如权利要求1中所定义。
  • Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds
    申请人:Boehringer Ingelheim International GmbH
    公开号:US07393843B2
    公开(公告)日:2008-07-01
    A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid β peptides (Aβ) and/or with a changed ratio of levels of Aβ isoforms and/or with the formation of plaques containing amyloid β peptide (Aβ) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R2, R3, R5, R6, L1 and i are defined as in claim 1.
    一种治疗或预防与哺乳动物中淀粉样β肽(Aβ)的异构体水平增高以及/或Aβ异构体水平比例改变和/或形成含有Aβ肽(Aβ)异构体的斑块相关的疾病或病症的方法,包括向该哺乳动物投与一种从公式Ia,Ib中选择的化合物的治疗有效量,其中V、W、Y、R2、R3、R5、R6、L1和i的定义如权利要求1所述。
  • Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds
    申请人:Boehringer Ingelheim Vetmedica GmbH
    公开号:US07375220B2
    公开(公告)日:2008-05-20
    A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid β peptides (Aβ) and/or with a changed ratio of levels of Aβ isoforms and/or with the formation of plaques containing amyloid β peptide (Aβ) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R2, R3, R5, R6, L1 and i are defined as in claim 1.
    一种治疗或预防与哺乳动物中淀粉样β肽(Aβ)的异构体水平增加以及/或Aβ异构体水平比例改变和/或形成含有Aβ肽(Aβ)异构体的斑块相关的疾病或症状的方法,包括向该哺乳动物施用公式Ia、Ib中选择的化合物的治疗有效量,其中V、W、Y、R2、R3、R5、R6、L1和i如权利要求1所定义。
  • US7375220B2
    申请人:——
    公开号:US7375220B2
    公开(公告)日:2008-05-20
查看更多

同类化合物

布林左胺 布林佐胺盐酸盐 布林佐胺杂质E 布林佐胺杂质C 布林佐胺杂质2 布林佐胺中间体 布林佐胺 布林佐胺 N-去乙基布林佐胺 6-氯-4-羟基-3,4-二氢-2H-噻吩并[3,2-e][1,2]噻嗪1,1-二氧化物 6-氯-2,3-二氢-4H-噻吩并[3,2-e]-1,2-噻嗪-4-酮1,1-二氧化物 6-乙酰基-1H-噻吩并[2,3-b][1,4]噻嗪-2(3H)-酮 4-羟基-2-甲基-2H-噻吩并[2,3-E]-1,2-噻嗪-3-甲酰胺1,1-二氧化物 3,4-二氢-4-羟基-2H-噻吩并[3,2-e]-1,2-噻嗪-1,1-二氧化物 2-(3-甲氧基丙基)-4-氧代-3,4-二氢-2H-噻吩并[3,2-e][1,2]噻嗪-6-磺酰胺1,1-二氧化物 2,3-二氢-4H-噻吩并[2,3-e][1,2]噻嗪-4-酮1,1-二氧化物 1,5,6-三甲基-1,2,3,4-四氢-2LAMBDA6-噻吩并[2,3-C][1,2]噻嗪-2,2,4-三酮 (S)-6-氯-3,4-二氢-2H-噻吩[3,2-E]-1,2-噻嗪-4-醇 1,1-二氧化氮 (S)-6-氯-2-(3-甲氧基丙基)-3,4-二氢-2H-噻吩并[3,2-e][1,2]噻嗪-4-醇 1,1-二氧化物 (S)-3,4-二氢-4-羟基-2-(3-甲氧丙基)-2H-噻吩并[3,2-E]-1,2-噻嗪-6-磺酰胺 1,1-二氧化物 (4S)-3,4-二氢-2-(3-甲氧基丙基)-2H-噻吩并[3,2-e]-1,2-噻嗪-4-醇 1,1-二氧化物 2,3-dihydro-4H-thieno[2,3-e][1,3]thiazine-4-thione 3-(2-isobutylaminoethyl)-2,3-dihydro-4,4-dioxo-6-sulfamoyl-1H-thieno[2,3-b][1,4]thiazine hydrochloride (R)-3,4-dihydro-2-(4-methoxybutyl)-4-propylamino-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide (S)-N-(1,1-dimethylethyl)-3,4-dihydro-4-hydroxy-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide N-(1,1-dimethylethyl)-2-[4-(4-morpholinyl)-2-butenyl]-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide 3,4-Dihydro-4-hydroxy-N-(1,1-dimethylethyl)-2-[4-(4-morpholinyl)-2-butenyl]-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide 6-chloro-3,4-dihydro-2-(4-bromobutyl)-2H-thieno[3,2-e]-1,2-thiazine-4-ol 1,1-dioxide 3,4-dihydro-2,6-dimethyl-3-oxo-2H-thieno[3,2-e]-1,2-thiazine-4-carboxanilide 1,1-dioxide (+)-4-Ethylamino-3,4-dihydro-2-methyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide (+)-4-Hydroxy-2-methyl-2,3-dihydro-4H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide 3,4-Dihydro-2-methyl-2H-thieno[3,2-e]-1,2-thiazine-4-ol-1,1-dioxide 3,4-Dihydro-4-hydroxy-2-(2-methoxy)ethyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide N-(1,1-Dimethylethyl)-3,4-dihydro-2-(4-methoxybutyl)-4-oxo-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide 2,3-Dihydro-N-(1,1-dimethylethyl)-4-oxo-4H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide N-(2-dimethylaminoethyl)-6-ethyl-2,3-dihydro-1H-thieno[2,3-b][1,4]thiazine-1-carboxamide N-(1,1-Dimethylethyl)-3,4-dihydro-4-hydroxy-2-(4-methoxybutyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide (S)-N-(1,1-Dimethylethyl)-3,4-dihydro-4-hydroxy-2-(4-methoxybutyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide 3,4-Dihydro-3-methyl-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide 2-methyl-3,4-dihydro-2H-thieno[2,3-e][1,2]thiazin-4-amine 1,1-dioxide 7-acetyl-1-phenyl-4H-thieno<2,3-b><1,2,4>triazolo<4,3-d><1,4>thiazine T 2097 3-Aethoxycarbonylmethyl-4-hydroxy-2-methyl-2H-thieno<2,3-e>-1,2-thiazin-1,1-dioxid 2-benzylthio-6-ethyl-3H-thieno<2,3-b><1,4>thiazine 2-[(4-methoxyphenyl)methyl]-3-[(4-morpholinyl)methyl]-2H-thieno[3,2-e]-1,2-thiazine 1,1-dioxide 3-[[Bis(2-methoxyethyl)amino]methyl]-2-ethyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide 3-Hydroxymethyl-2-(1-methylethyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide 3-[[(2-methoxyethyl)(3-methoxypropyl)amino]methyl]-2-methyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide 2-(Cyclopropylmethyl)-3-(4-morpholinylmethyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1 dioxide 3-(4-Morpholinylmethyl)-2-propyl-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide